56.56
전일 마감가:
$57.29
열려 있는:
$57.28
하루 거래량:
1.06M
Relative Volume:
0.52
시가총액:
$10.85B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
21.03
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-2.87%
1개월 성능:
+2.84%
6개월 성능:
-9.55%
1년 성능:
-32.74%
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BMRN
Biomarin Pharmaceutical Inc
|
56.56 | 11.17B | 2.95B | 523.88M | 620.18M | 2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-03 | 재개 | Morgan Stanley | Overweight |
2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2024-05-14 | 개시 | Evercore ISI | Outperform |
2023-11-15 | 개시 | Wells Fargo | Overweight |
2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
2023-09-28 | 개시 | Raymond James | Mkt Perform |
2023-09-18 | 개시 | UBS | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Perform |
2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-06-14 | 재개 | Credit Suisse | Outperform |
2023-03-21 | 개시 | Bernstein | Underperform |
2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2023-02-21 | 개시 | Citigroup | Neutral |
2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
2023-01-18 | 개시 | Canaccord Genuity | Hold |
2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
2022-06-13 | 재개 | Wedbush | Neutral |
2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2021-10-07 | 재개 | Jefferies | Buy |
2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
2021-06-04 | 재개 | Robert W. Baird | Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-03-04 | 재개 | Guggenheim | Buy |
2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-07-06 | 재확인 | Citigroup | Buy |
2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-11-12 | 개시 | SunTrust | Buy |
2019-10-17 | 재개 | BofA/Merrill | Buy |
2019-05-23 | 재개 | Citigroup | Buy |
2019-04-09 | 재개 | Raymond James | Outperform |
2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2018-12-14 | 개시 | Wolfe Research | Outperform |
2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
2018-08-07 | 재확인 | Stifel | Buy |
2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
What analysts say about BioMarin Pharmaceutical Inc. stockTremendous growth potential - jammulinksnews.com
BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize
What drives BioMarin Pharmaceutical Inc. stock priceConsistently superior profits - jammulinksnews.com
BioMarin Pharmaceutical Inc. Stock Analysis and ForecastUnmatched market performance - jammulinksnews.com
Is BioMarin Pharmaceutical Inc. a good long term investmentDynamic investment growth - jammulinksnews.com
BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria
What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks
BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com
The Top 12 Companies Hiring in Biopharma Now - BioSpace
The Best Biotech Stocks to Buy - Morningstar
BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com
BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener
BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan
BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index - MarketScreener
BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A - MSN
11 Most Undervalued US Stocks According to Analysts - Insider Monkey
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies - Reuters
BioMarin sees long-term strength in Roctavian data - The Pharma Letter
BioMarin’s hemophilia gene therapy shows sustained results at 5 years - Investing.com
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating - Yahoo Finance
2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance
Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan
BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader
Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN
BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga
BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights - TipRanks
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):